VANCOUVER, British Columbia, July 8, 2026
Cannabix Technologies Inc. and Omega Laboratories announced the development and validation of a breath-based DOT-like drug testing panel capable of detecting multiple drug classes using breath aerosols collected with the Cannabix Breath Collection Unit. The new laboratory-validated method extends Omega’s existing breath-testing capabilities beyond cannabinoids, enabling simultaneous detection of amphetamines, methamphetamines, cocaine, marijuana, opiates, and phencyclidine (PCP). Modeled after the U.S. Department of Transportation (DOT) federally mandated urine drug testing panel, the new approach is designed to identify recent drug use rather than historical exposure, providing employers, courts, treatment programs, schools, and other safety-sensitive organizations with a more time-relevant testing option for workplace and forensic applications.
Laboratory-Based Breath Testing Focuses on Minutes-to-Hours Detection Window
Unlike conventional testing methods such as urine, oral fluid, and hair analysis, which can detect drug use over periods ranging from days to months, the newly validated breath-testing platform is designed to identify drug use within a much shorter timeframe, typically minutes to hours after consumption. This makes the technology particularly valuable for reasonable suspicion investigations, post-incident testing, random workplace screening, criminal justice programs, forensic examinations, and other safety-sensitive environments where determining recent impairment is more important than identifying historical drug use. According to Omega Laboratories, the expanded panel addresses increasing demand for testing methods that better distinguish recent use, especially as marijuana legalization continues to reshape workplace drug-testing policies while maintaining the ability to evaluate multiple controlled substances through a single breath sample.
Mass Spectrometry Validation Strengthens Scientific Accuracy and Defensibility
Omega’s laboratory-based breath testing utilizes mass spectrometry, a gold-standard analytical technology widely used for confirmatory toxicology testing due to its high sensitivity and specificity. Samples are collected using the Cannabix Breath Collection Unit and Breath Cartridge System, which incorporates multiple safeguards including startup airflow verification, ambient air sampling to minimize environmental contamination, and split A/B sample collection to support confirmatory testing and chain-of-custody requirements. Rather than providing rapid onsite screening, the companies intentionally developed the system as a laboratory-based testing solution capable of delivering the analytical precision, legal defensibility, and forensic reliability required for workplace compliance programs, law enforcement, and judicial proceedings. This approach enables organizations to obtain scientifically validated results while preserving evidentiary integrity throughout the testing process.
Advertisement
Expanded Drug Panel Builds on Published Cannabinoid Breath Testing Research
The newly announced DOT-like multi-drug panel builds upon previously published peer-reviewed research by Cannabix and Omega in the Journal of Analytical Toxicology, which validated laboratory detection of Δ9-THC, Δ8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols collected using the Cannabix platform. By extending laboratory validation to additional drug classes commonly included in federally regulated workplace testing programs, the companies are expanding the clinical and forensic applications of breath-based toxicology. Omega stated that both its existing THC breath test and the expanded multi-drug testing panel are now available to new and existing clients. The companies believe laboratory-based breath testing could become an important complement to traditional drug-testing methods by providing scientifically supported, time-relevant detection of recent drug use, helping organizations make more informed safety and compliance decisions while reducing reliance on tests that primarily reflect past substance exposure.
Source: Cannabix Technologies, press release
